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Abstract Regulating dietary fat absorption may
impact progression of nonalcoholic fatty liver dis-
ease (NAFLD). Here, we asked if inducible inhibition
of chylomicron assembly, as observed in intestine-
specific microsomal triglyceride (TG) transfer pro-
tein knockout mice (Mttp-IKO), could retard NAFLD
progression and/or reverse established fibrosis in
two dietary models. Mttp-IKO mice fed a methionine/
choline-deficient (MCD) diet exhibited reduced he-
patic TGs, inflammation, and fibrosis, associated
with reduced oxidative stress and downstream acti-
vation of c-Jun N-terminal kinase and nuclear factor
kappa B signaling pathways. However, when Mttpflox
mice were fed an MCD for 5 weeks and then
administered tamoxifen to induce Mttp-IKO, hepatic
TG was reduced, but inflammation and fibrosis were
increased after 10 days of reversal along with adap-
tive changes in hepatic lipogenic mRNAs. Extending
the reversal time, following 5 weeks of MCD feeding
to 30 days led to sustained reductions in hepatic TG,
but neither inflammation nor fibrosis was decreased,
and both intestinal permeability and hepatic lipo-
genesis were increased. In a second model, similar
reductions in hepatic TG were observed when mice
were fed a high-fat/high-fructose/high-cholesterol
(HFFC) diet for 10 weeks, then switched to chow ±
tamoxifen (HFFC → chow) or (HFFC → Mttp-IKO
chow), but again neither inflammation nor fibrosis
was affected. In conclusion, we found that blocking
chylomicron assembly attenuates MCD-induced
NAFLD progression by reducing steatosis, oxida-
tive stress, and inflammation. In contrast, block-
ing chylomicron assembly in the setting of
established hepatic steatosis and fibrosis caused
increased intestinal permeability and compensatory
shifts in hepatic lipogenesis that mitigate resolution
of inflammation and fibrogenic signaling despite
50–90-fold reductions in hepatic TG.
Supplementary key words intestine • lipid absorption •
antioxidant • apolipoprotein B • lipoproteins • microsomal
triglyceride transfer protein • fibrosis • oxidative stress •
intestinal permeability • hepatic lipogenesis
Nonalcoholic fatty liver disease (NAFLD) is the most
common form of chronic liver disease worldwide,
affecting more than a quarter of the US population (1).
A subset of patients with NAFLD will progress to
develop nonalcoholic steatohepatitis (NASH) with
inflammation and fibrosis, and a further subset will
develop cirrhosis and hepatocellular cancer, through
mechanisms and pathways that have yet to be fully
understood (2). The pathogenesis of NAFLD and its
progression to NASH involves genetic and environ-
mental interactions (3) as well as signaling events be-
tween and among cells in the liver (hepatocytes, stellate
cells, and resident and circulating immune cells) and
with other organs such as adipose tissue and intestine
(2). Altered homeostatic signaling across the gut-liver
axis affects hepatic lipid metabolism as well as
immune signaling and inflammation, through mecha-
nisms including (but not limited to) altered fat absorp-
tion, changes in gut microbiota, disrupted intestinal
permeability, incretin, and bile acid signaling (4, 5).
Those findings have promoted interest in strategies for
prevention and resolution of NASH by targeting the
gut-liver axis, with findings in preclinical models and
human subjects showing attenuated hepatic steatosis
but no consistent or sustained effects on hepatic
inflammation and fibrosis (6–8). Studies in preclinical
models support a role for alterations in gut-liver
signaling in the progression of NASH, including work
showing that mice fed high-fat diets and exposed to
dextran sodium sulfate develop increased gut bacterial
translocation and worsened hepatic fibrosis (9). Other
work has highlighted a role for inflammasome
signaling associated with altered gut microbial taxa in
promoting hepatic steatosis and inflammation (10).
In regard to the impact of impaired intestinal lipid
transport on NAFLD, we and others have shown that
mice with conditional intestinal deletion of microsomal
triglyceride (TG) transfer protein (Mttp-IKO) demon-
strate impaired chylomicron assembly and decreased
intestinal fat (TG and cholesterol) absorption with
decreased hepatic steatosis, despite increased hepatic de
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novo lipogenesis (DNL) and increased VLDL secretion
(11–13). In addition, conditional Mttp-IKO mice are pro-
tected from developing fructose-induced hepatic stea-
tosis through multiple adaptations including increased
incretin secretion, altered microbial taxa, and shifts in
bile acid signaling (14). However, the extent to which
inducible impairment of chylomicron assembly and
altered gut-liver signaling in Mttp-IKO mice mitigates
either the development or the reversal of hepatic
inflammation and fibrosis is unknown. Other findings
in the setting of impaired chylomicron assembly and
secretion suggest that intestinal Mttp deletion impairs
immune signaling in both mice and humans (15, 16). In
addition, yet other findings suggest that Mttp-IKO mice
exhibit a greater intestinal tumor burden in colitis-
associated cancer (17). Those findings collectively
point to a series of adaptations in immune signaling
and inflammation in Mttp-IKO mice that could
conceivably exaggerate fibrogenic signaling and exac-
erbate liver injury in mice, even in the absence of
established steatosis and fibrosis.
Here, we asked if inducible deletion of chylomicron
assembly in Mttp-IKO mice could mitigate NAFLD/
NASH progression and/or reverse established fibrosis,
using an approach incorporating two distinct dietary
models. In the first model, we fed mice a methionine/
choline-deficient (MCD) diet as a model of inflamma-
tory and fibrogenic injury (18). MCD feeding induces a
robust fibrogenic response but does not replicate other
features of NAFLD including obesity and insulin resis-
tance (18). In the second model, we fed mice a high-fat,
high-fructose, high-cholesterol (HFFC) diet, which is a
nutritional model of obesity-associated steatosis and
fibrogenic injury (19, 20). Our findings show that block-
ing lipid absorption attenuates MCD-induced NAFLD
progression by reducing steatosis, oxidative stress, and
inflammation. However, while blocking lipid absorption
decreases established steatosis in both dietary models,
with over a >90-fold range of hepatic TG content,
fibrosis, and inflammation were unchanged. Our find-
ings suggest that increased intestinal permeability and
compensatory shifts in hepatic lipogenesis likely combine
to promote continued inflammation and fibrogenic
signaling despite the reduction in hepatic steatosis.
MATERIALS AND METHODS
Animals and diets
All animal protocols were approved by the Washington
University IACUC and conformed to standards outlined in
the Guide for the Care and Use of Laboratory Animals (the
National Institutes of Health, 1985) and conducted in accor-
dance with institutional guidelines (IACUC #20180284). Mice
were housed in ventilated cages on a 12 h light/dark cycle
with corncob bedding and ad libitum access to rodent chow
(PicoLab Rodent Diet 20; LabDiet, St Louis, MO) and water
unless otherwise noted. Mttpf/f Villin Cre ERT2 mice (11) were
injected with tamoxifen (TAM) at 50 μg/g body
weight/day/5 days with littermates receiving vehicle injection
as control. Both male and female mice were used, with the
majority of experiments conducted in male mice as indicated
in the relevant legends to the figures (11). In a first dietary
model, 12–16-week-old Mttpf/f Villin Cre ERT2 mice were fed
MCD (MP Biomedicals, LLC; catalog no.: 960439) for 3 weeks,
starting 3 weeks after TAM or vehicle injection. Where indi-
cated, other groups of Mttpf/f Villin Cre ERT2 mice were fed
MCD for 5 weeks with groups of mice subsequently injected
with TAM or vehicle and sacrificed either 10 days later (while
consuming MCD) or switched to regular rodent chow and
sacrificed 35 days later. In a second dietary model,
Mttpf/f Villin Cre ERT2 mice were fed an HFFC diet (Research
Diets, Inc; catalog no.: D09100301) for 10 weeks, then switched
to regular rodent chow and injected with either TAM or
vehicle, and sacrificed 35 days later. At sacrifice, blood and
tissues were collected after 4–6 h fasting and frozen at −80oC.
Portions of freshly isolated tissue were taken for processing as
described later.
Histologic analysis
Livers were fixed in 10% neutral-buffered formalin,
sectioned, and stained with H&E or used for Sirius red or anti-
F4/80 antibody immunohistochemical staining (1:100 dilution)
as previously detailed (20, 21) using Nuance 2.10 multispectral
imaging (PerkinElmer) or ImageJ software (the National In-
stitutes of Health).
Hepatic lipid, collagen content, and oxidative stress
parameters
Hepatic TG, cholesterol, and FFAs were determined enzy-
matically using commercial kits (FUJIFILM Wako Diagnostics,
Richmond, VA) as previously described (20, 21). Hepatic
collagen content was determined using a commercial kit
(QuickZyme Biosciences; catalog no.: QZBTOTCOL1),
following instructions with minor modifications. In brief,
about 80 mg of snap-frozen liver was homogenized in 1 ml
water, and an equal volume of 12 N HCl added to the ho-
mogenate and hydrolyzed at 95oC for 20 h. Collagen content
in the mixture was measured spectrometrically and normal-
ized to protein content. Hepatic lipid hydroperoxide and
glutathione levels were measured on fresh liver samples after
homogenization using a commercial kit (catalog Nos.: 705002
and 705003; lipid hydroperoxide assay kit [catalog no.: 703002];
glutathione assay kit [Cayman Chemical, Ann Arbor, MI]).
Hepatic thiobarbituric acid reactive substances (TBARS) were
determined by Parameter™ TBARS kit (R&D Systems; catalog
no.: KGE013) following the manufacturer's instructions with
modifications for use on lipid-rich samples. In brief, liver
lipids were extracted by chloroform:methanol (2:1). The
organic phase was dried under nitrogen and redissolved in 1%
Triton. TBARS in the mixture were determined spectro-
metrically following the manufacturer's instructions.
RNA extraction, sequencing, and quantitative PCR
For each genotype and condition, three pools were pre-
pared, each containing RNAs from three to four separate
mice, for a total of 10 μg RNA per final pool. Pools were
sequenced on an Illumina HiSeq system. Base calls and
demultiplexing were performed with Illumina's bcl2fastq
software and a custom python demultiplexing program with
a maximum of one mismatch in the indexing read. RNA-Seq
reads were then aligned to the Ensembl release 76 primary
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assembly with STAR, version 2.5.1a (22). Gene counts were
derived from the number of uniquely aligned unambiguous
reads by Subread:feature Count, version 1.4.6-p5 (23). Isoform
expression of known Ensembl transcripts was estimated with
Salmon, version 0.8.2 (24). Sequencing performance was
assessed for the total number of aligned reads, total number
of uniquely aligned reads, and features detected. The ribo-
somal fraction, known junction saturation, and read distri-
bution over known gene models were quantified with RSeQC,
version 2.6.2 (25). For quantitative PCR determination, RNA
was extracted using TRIzol® Reagent (Invitrogen Life Tech-
nologies, Carlsbad, CA) and treated with DNase. Genes
exhibiting differential regulation were selected and used as
input to String-db.org for functional protein association
network analysis. Reverse transcription was performed using
the ABI high-capacity complementary DNA reverse tran-
scription kit (catalog no.: 4368814), with ∼1 μg of total RNA
and random hexamers, to generate complementary DNA.
qRT-PCR assays were performed in triplicate on a Step One
Plus Sequence Detection System using Fast SYBR Green
Master Mix (catalog no.: 4385612; Applied Biosystems). Primer
pairs were designed by Primer Express software 3.0 (Applied
Biosystems), with sequences listed in supplemental Table S1.
Relative mRNA abundance was validated in a subset of tar-
gets using qRT-PCR and expressed as fold change compared
with mRNA levels in control mice, normalized to GAPDH.
Intestinal permeability
Mice were administered FITC-labeled dextran (FD-4; mo-
lecular weight 4,000; Millipore Sigma; catalog no.: FD4) by oral
gavage (400 mg/kg body weight) as described previously (17),
with FD-4 levels measured in serum collected 2 and 4 h after
gavage using fluorimetry (Synergy HT; BioTek®) at excita-
tion of 485/20 and emission of 528/20. Serum levels of
alanine aminotransferase (ALT) and aspartate aminotrans-
ferase were measured with kits following manufacturer's in-
structions (catalog no.: A526-120 and A561-120; TECO
DIAGNOSTICS, Anaheim, CA).
Targeted hepatic lipidomic survey
Liver samples were homogenized in PBS (1:4 w/v) using an
Omni bead ruptor (PerkinElmer), and lipid extracted using a
modified Bligh-Dyer method (20). Internal standards included
ceramide (Cer) (17:0), TG (17:0-17:0-17:0), diglyceride/diac-
ylglycerol (21:0-21:0), phosphatidylcholine (14:1-14:1), and d4-
FFA (16:0), respectively. Internal standards were added to all
samples before extraction. Three blank samples were pre-
pared and run with the study samples for FFA assay, with the
average signal of FFA in blank sample subtracted to eliminate
artifactual interference. Quality control (QC) samples were
prepared by pooling aliquots of the study samples and used to
monitor the instrument stability. The QC was injected three
times in the beginning to stabilize the instrument and was
injected between every four study samples. Only lipid species
with coefficient of variation <15% in QC sample were re-
ported. Measurement of FFA was performed with a Shimadzu
20A HPLC system and a Shimadzu SIL20AC HT autosampler
coupled to a 4000QTRAP mass spectrometer operated in
positive multiple reaction monitoring mode. Measurement of
phosphatidylcholine, diglyceride/diacylglycerol, TG, and Cer
was performed with a Shimadzu 20A HPLC system and a
Shimadzu SIL-20AC HT autosampler coupled to an API4000
mass spectrometer operated in positive multiple reaction
monitoring mode. Data processing was conducted with
Analyst 1.6.3 (AB Sciex). The relative quantification of lipids
was undertaken with data reported as the peak area ratios of
the analytes relative to the corresponding internal standards.
DNL index, FA elongation index, and steroyl CoA desaturase
(SCD) index were calculated using FA chain length and
saturation parameters as previously detailed (20, 26, 27). DNL
index is the ratio of FFA 16:0 to 18:2; SCD index is the ratio of
(16:1 + 18:1) divided by (16:0 + 18:0); FA elongation index is the
ratio of (18:0 + 18:1) divided by (16:0 + 16:1). The comparison of
individual lipid species (peak area ratio) was performed using
a multiple unpaired t-test using GraphPad Prism 9.0.0
(GraphPad Software, Inc).
Statistical analysis
Data were analyzed using GraphPad Prism 9.0.0 by un-
paired t-test or Mann-Whitney U test. For multigroup com-
parisons, statistical differences were determined by one-way
analysis of variance and Tukey's multiple comparison post
hoc test. Pearson correlation coefficients were calculated
based on the hepatic TG and fibrotic area by GraphPad Prism
9.0.0. The level of significance was set at P < 0.05.
RESULTS
Mttp-IKO mice fed an MCD diet exhibit reduced
hepatic steatosis, inflammation, and fibrosis
Mice of both genotypes (WT littermate controls and
TAM-treated Mttpf/f Villin Cre ERT2 mice) were fed an
MCD diet for 3 weeks, revealing macrovesicular steatosis
(Fig. 1A) with Mttp-IKO mice showing ∼80% reduction
(1,700 → 385 μg/mg protein) in hepatic TG content as
well as reduced cholesterol and FFA (Fig. 1B). Hepatic
FA species distribution was altered in Mttp-IKO mice
with reduced abundance of polyunsaturated FAs (C18:2,
20:4) evident in both TGs and FFAs (Fig. 1C, D), with a
corresponding increase in DNL, SCD, and elongation
indices (Fig. 1D). An adaptive increase in hepatic DNL is
consistent with our prior findings in chow-fed Mttp-IKO
mice (11). Hepatic inflammation and fibrosis were also
reduced inMttp-IKOmice as evidenced by reduced Sirius
red and F4/80 staining (Fig. 1E, F), despite the increase
in serum transaminases (Fig. 1G) and increased intestinal
permeability (Fig. 1H) in Mttp-IKO mice. In line with the
reduced Sirius staining, hepatic collagen content was
reduced greater than 4-fold in Mttp-IKO mice
(supplemental Fig. S1). Hepatic transcriptomic profiling
was consistent with decreased inflammatory (F4/80 and
Cx3cr1) and fibrogenic (Col1a1, Sma, and Desmin)
signaling and increased DNL (Scd1, Scd2, and Fasn) in
Mttp-IKO mice (Fig. 1I). These findings demonstrate that
blocking chylomicron assembly mitigates hepatic stea-
tosis and reduces both inflammatory and fibrogenic
signaling following MCD feeding.
Reduced oxidative stress, c-Jun N-terminal kinase,
and nuclear factor kappa B activation in Mttp-IKO
mice-fed MCD diet
We next undertook transcriptomic profiling using
RNA-Seq to understand in more detail the signaling
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Fig. 1. Conditional intestinal Mttp deletion prevents hepatic steatosis, fibrosis, and inflammation in male mice-fed MCD for 3 weeks.
A: Representative images of H&E-stained liver tissue at 50× (upper panels) and 400× magnification. B: Biochemical quantitation of
hepatic lipid content, including TG, FFAs, and total cholesterol (TC) (n = 11/genotype). C: Relative abundance of the most abundant
TG species presented as peak area ratio (n = 4/group). D: Relative abundance of the most abundant FFA species presented as peak
area ratio (left panel). Right panel shows indices of DNL, FA saturation (SCD), and elongation (n = 4/genotype) calculated from peak
area of all FFA species. E: Representative images of Sirius red-stained liver tissue (200× magnification). Right panel shows quanti-
tation of fibrotic area, expressed as percent of total tissue area (n = 11/genotype). F: Representative images of F4/80 staining (400×).
Right panel shows quantitation of F4/80-stained area expressed as percent of total tissue area (n = 11/genotype). G: Serum AST (left)
and ALT levels (n = 11/genotype). H: Serum FITC-dextran (FD4) levels 2 h after oral gavage (n = 3–7/genotype). I: mRNA expression
of genes related to fibrosis, inflammation, and lipogenesis (n = 4–11/genotype). For all panels, data are presented as mean ± SEM,
with * indicating P < 0.05 and ** indicating P < 0.01. AST, aspartate aminotransferase.
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Fig. 2. Intestinal Mttp deletion attenuates expression of liver damage-associated molecular patterns (DAMPs) and oxidative stress
induced by MCD feeding in male mice. A: Heat map of 290 differentially expressed genes (log fold change [FC] ≥ ±2) in control and
Mttp-IKO liver. B: STRING analysis of 205 differentially expressed genes with log (FC) ≤ −2 showing enriched pathways. C–E:
Quantitative PCR validation of gene clusters involved in cell division (C), oxidative stress (D), and DAMP and inflammation (E)
associated STRING pathways. F: Expression of total and phosphorylated JNK and NF-κB proteins in control and Mttp-IKO liver tissue.
A representative Western blot (left) and quantitation of protein levels relative to controls after normalization to loading controls
(GAPDH or ACTIN) are shown. G: Biochemical determination of hepatic lipid hydroperoxide (LPO, left panel) and TBARS (middle)
levels. Right panel shows ratio of GSH to GSSG. For all bar graphs, data are presented as mean ± SEM, with n = 4–9/genotype. *P <
0.05 and **P < 0.01.
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pathways involved in mitigating inflammatory and
fibrogenic injury in MCD-fed Mttp-IKO mice. Heat map
and STRING analysis (Fig. 2A, B) revealed several
groups of altered mRNAs including histone modifiers
and cell cycle genes (Kif23, Aurkb, Hist1h1a, and
Hist1h3d; Fig. 2C), oxidative stress modifiers (Hmox1
and Gss; Fig. 2D), and damage-associated molecular
pathways/inflammatory signaling genes (Tnfa, Tlr4,
Tlr7, Tlr12, S100A4, and S100A10; Fig. 2E). We further
confirmed a role for altered inflammatory signaling
through c-Jun N-terminal kinase (JNK) and nuclear
factor kappa B (NF-κB)-related pathways, demon-
strating reduced activation (decreased phospho-
JNKp46, p54, and phosphorylated NF-κB; Fig. 2F).
Similarly, we found reduced TBARS in MCD-fed Mttp-
IKO mice, without a change in overall antioxidative
capacity as evidenced by the glutathione/GSSG ratio
(Fig. 2G). Those findings, coupled with the aforemen-
tioned observations, suggest that blocking chylomicron
assembly in MCD-fed Mttp-IKO mice reduces hepatic
steatosis and mitigates inflammatory and fibrogenic
signaling through a combination of pathways,
including altered cell signaling, damage-associated
molecular pathway, and oxidative stress pathways.
Conditional intestinal Mttp deletion reverses
steatosis but not inflammation or fibrosis in MCD-
fed mice
Based on the aforementioned demonstration that
blocking chylomicron assembly produced a significant
effect on the development of hepatic steatosis and
inflammatory-fibrogenic signaling, we asked if condi-
tional intestinal Mttp deletion would also reverse those
phenotypes, once established. We fed groups of Mttpf/f
Villin Cre ERT2 mice an MCD diet for 5 weeks to induce
steatosis, inflammation, and fibrosis (Fig. 3A) and then
treated mice with either TAM or vehicle and studied
them after a further 10 days of MCD feeding. Even this
short period of blocked chylomicron assembly pro-
duced >90% reduction in hepatic TG content (Fig. 3B),
which was accompanied by an increase in both fibrosis
(Fig. 3C) and hydroxyproline content (28 ± 2 → 69 ±
10 μg/mg protein; P < 0.01) despite decreased F4/80
staining (Fig. 3D). TG FA distribution showed a similar
shift as noted previously in MCD-fed Mttp-IKO mice
(compare Fig. 3E with Fig. 1C), along with increased
DNL (Fig. 3E, F). Transcriptomic markers of fibrogenic
(Col1a1, Sma, Tgfb, and Desmin) and inflammatory
signaling genes (Tnfa and Loxl1) showed inconsistent
changes with either a decrease or no change in MCD-
fed Mttp-IKO mice (Fig. 3F), whereas markers of JNK
and NF-κB signaling likewise were decreased or un-
changed (Fig. 3G). In addition, markers of hepatic
inflammation (ALT and aspartate aminotransferase)
and intestinal permeability were increased in MCD-fed
Mttp-IKO mice (Fig. 3H, I). Those findings suggest that
short-term (10 days) induction of blocked chylomicron
assembly in the setting of established steatosis and
fibrosis produces substantial reductions in hepatic TG
but no consistent improvement in inflammatory or
fibrogenic signaling. The relatively brief time frame
for this intervention raised the possibility that resolu-
tion of the inflammatory and fibrogenic signaling
components of liver injury with MCD feeding might
require an extended period following reduction of
hepatic steatosis.
Based on those possibilities, we next asked if
extending the time following induction of blocked
chylomicron assembly would permit further resolu-
tion of the inflammatory/fibrogenic injury pheno-
type. Our initial studies extending the period
following TAM administration with Mttp-IKO mice
consuming an MCD diet revealed continued weight
loss and increased lethality (data not shown). To
circumvent this problem, we elected to feed groups of
Mttpf/f Villin Cre ERT2 mice an MCD diet for 5 weeks,
then switched them to regular chow with either TAM
or vehicle administration, and studied them after a
further 4 weeks (Fig. 4A). Weight gain resumed in
both groups upon switching to chow, although lower
in Mttp-IKO versus control mice (supplemental
Fig. S2A). Both groups demonstrated reduction in he-
patic TG content after 4 weeks of chow feeding, but
hepatic TG was again lower in Mttp-IKO versus control
mice (Fig. 4B). Fibrosis, assessed by Sirius red staining
and histopathologic review, was no different between
groups (Fig. 4C) nor was there a difference in F4/80
staining (Fig. 4D). The TG FA species distribution
again recapitulated findings from earlier studies
(Figs. 1C, 3E), and DNL, SCD, and FA elongation indices
were all increased in Mttp-IKO mice (Fig. 4E). In addi-
tion, we observed an increase in both total hepatic Cer
content as well as in 16:0, 18:0, 18:1, and 24:1 species in
Mttp-IKO mice, with a relative decrease in 20:0 and 22:0
species (Fig. 4F). Those changes were further extended
with transcriptomic profiles showing increased mRNA
abundance of CerS4, CerS5, CerS6 (Fig. 4F, right
panel) as well as Scd1, Scd2, and Fasn in livers of Mttp-
IKO mice (Fig. 4G). By contrast, other parameters of
inflammatory (Tnfa and Loxl1) and fibrogenic (Col1a1,
Sma, and Tgfb) signaling were no different by geno-
type (Fig. 4G) nor were there differences by genotype
in JNK and NF-κB signaling (Fig. 4H). Those findings
suggest that those signaling pathways identified pre-
viously in the preventive experiments (Figs. 1I, 2A–E)
were not modified in the setting of conditionally
impaired chylomicron assembly following established
steatosis and fibrosis. As in the preventive experiments
(Fig. 1G, H), serum ALT and FD-4 levels were increased
in Mttp-IKO mice following reversal to chow, suggest-
ing hepatocyte injury and impairment of intestinal
barrier function (Fig. 4I, J), as well as upregulated
expression of a subset of immune response genes
(supplemental Fig. S3A).
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Fig. 3. Short-term (10 days) intestinal Mttp deletion mitigates hepatic steatosis but not fibrosis. A: Schematic diagram of experi-
mental design. B: Biochemical quantitation of hepatic lipid content (n = 11–13/genotype). C: Representative images of Sirius red-
stained liver tissue (200×) and quantitation of fibrotic area (right panel, n = 11–13/genotype; both male and female mice). D:
Representative images of hepatic F4/80 staining (400×) and quantitation of F4/80-stained area (right panel, n = 7–9/genotype; both
male and female mice). E: Relative abundance of the most abundant TG species presented as peak area ratio, with DNL, SCD, and
elongation indices calculated from all TG species shown on right (n = 4/genotype). F: mRNA expression of genes related to fibrosis,
inflammation, and lipogenesis (n = 7–13/genotype). G: Expression of total and phosphorylated JNK and NF-κB proteins in control
and Mttp-IKO liver tissue. Representative Western blot (left) and quantitation of relative protein levels are shown, with levels of
GAPDH as a loading control. H: Serum ALT (left) and AST levels (n = 9/genotype). I: Serum FITC-dextran (FD4) levels 2 h after oral
gavage (n = 6/genotype). For all panels, data are presented as mean ± SEM. *P < 0.05 and **P < 0.01.
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Fig. 4. Switching from MCD to chow reverses steatosis but not inflammatory or fibrogenic signaling in male mice with intestinal
Mttp deletion. A: Schematic diagram of experimental design. B: Biochemical quantitation of hepatic lipid content (n = 5–10/geno-
type). C: Representative images of Sirius red-stained liver tissue (200×) and quantitation of fibrotic area (right panel, n = 10/ge-
notype). D: Representative images of hepatic F4/80 staining (400×) and quantitation of F4/80-stained area (right panel, n = 6/
genotype). E: Relative abundance of the most abundant TG species presented as peak area ratio (n = 4/group). Right panel shows
indices of lipogenesis (DNL), saturation, and elongation calculated from the relative abundance of all TG species. F: Relative
abundance of hepatic ceramide (Cer) species, with total Cer peak area ratio shown on the far right. Right panel shows mRNA
expression of Cer synthase isoforms in liver tissue. G: mRNA expression of genes related to fibrosis, inflammation, and lipogenesis
(n = 6/genotype). H: Levels of total and phosphorylated JNK and NF-κB protein in →chow and →IKO chow liver tissue. A repre-
sentative immunoblot and quantitation of relative expression are shown, with GAPDH presented as a loading control. n = 5/ge-
notype (I) serum ALT (left) and AST levels. n = 5/genotype. J: Serum FITC-dextran FD4 levels 2 h after oral gavage. For all bar
graphs, *P < 0.05 and **P < 0.01.
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Conditional intestinal Mttp deletion reverses
steatosis but not inflammation or fibrosis in
HFFC-fed mice
We next turned to an alternative dietary model of
NAFLD/NASH with inflammation and fibrosis, using a
HFFC model, which has been utilized in various subtle
iterations by several investigators (19, 20, 28–30). After
10 weeks of feeding, groups of Mttpf/f Villin Cre ERT2
mice were either maintained on HFFC as control or
transitioned to a regular chow diet with (+TAM) or
without (+vehicle) induction of intestinal Mttp deletion
for a further 4 weeks. As shown in Fig. 5A, 14 weeks of
HFFC feeding induced gross macrovesicular steatosis
and periportal and pericentral fibrosis (Fig. 5C), along
with diffuse F4/80 staining (Fig. 5E). Upon switching to
a chow diet, we observed weight loss in Mttp-IKO mice
(supplemental Fig. S2B). Groups of Mttpf/f Villin Cre
ERT2 (vehicle injected and control) and Mttp-IKO mice
transitioned to a chow diet for 4 weeks showed
a striking reduction in hepatic steatosis (Fig. 5A), with
a greater reduction in Mttp-IKO mice (1,200 ± 153 → 294
± 34 control vs. 102 ±15 μg/mg protein in Mttp-IKO), and
a concomitant decrease in hepatic content of TG,
cholesterol, and FFA (Fig. 5B). However, despite the
reversal of hepatic steatosis in both groups, there were
no significant changes in fibrosis—as assessed by either
Sirius staining (Fig. 5C) or hepatic hydroxyproline
content (Fig. 5D). Likewise, there was no significant
change in F4/80 staining in either of the groups
switched to chow (Fig. 5E). There were differential
shifts in TG FA species in Mttpf/f Villin Cre ERT2
(vehicle injected and control) and Mttp-IKO mice tran-
sitioned to a chow diet (Fig. 5F), predominantly
involving polyunsaturated FA species. In addition, and
similar to the adaptations observed previously in MCD-
fed mice, indices of DNL, SCD, and FA elongation were
all increased in chow-Mttp-IKO mice (Fig. 5G). Total
hepatic Cer content was also higher in HFFC-fed mice
transitioned to chow with induction of Mttp-IKO, with
selective increases in C16:0, C18:0, and C24:1 ceramides
in chow-Mttp-IKO mice (Fig. 5H). In line with the
changes in hepatic Cer content, mRNA expression of
hepatic CerS6 was increased in chow-fed Mttp-IKO mice
(Fig. 5I).
We found no changes in hepatic TBARS in any of
the groups fed HFFC diet (Fig. 6A), in contrast to the
findings in MCD-fed mice. Similarly, there was no
change in serum ALT across the HFFC-fed groups
(Fig. 6B). Intestinal permeability was increased in Mttpf/f
Villin Cre ERT2 mice fed HFFC, which was reversed
upon transition to chow (Fig. 6C), whereas chow-fed
Mttp-IKO mice exhibited a continued increase in intes-
tinal permeability (Fig. 6C). Hepatic transcriptomic
profiling revealed a nonsignificant trend to increased
Col1a1 and increased Tgfb, and Desmin mRNA abun-
dance in chow-fed Mttp-IKO mice, along with increased
F4/80 mRNA (Fig. 6D). We also observed alterations in
a subset of hepatic immune response gene in chow-fed
Mttp-IKO mice (supplemental Fig. S3B). Consistent with
the increased DNL index, Mttp-IKO mice also exhibited
increased Fasn expression (Fig. 6D). Parameters of JNK
and NF-κB activation were not significantly different
by genotype in either group transitioned to chow diet
(Fig. 6E). These findings, considered together with the
histologic and aforementioned lipidomic data, suggest
two major conclusions. First, the inflammatory
signaling and fibrosis accompanying HFFC feeding is
less severe than observed with MCD feeding, and sec-
ond, despite almost complete resolution of hepatic
steatosis, there is ongoing inflammatory and fibrogenic
signaling that perpetuates the underlying injury phe-
notypes. We found that hepatic steatosis, reflected by
hepatic TG content, was positively correlated (as ex-
pected) with development of fibrosis in animals fed an
MCD diet (Fig. 7A). However, over a >50–90-fold range
of hepatic TG, there was no correlation between he-
patic steatosis and fibrosis following the reversal in-
terventions in either MCD-fed or HFFC-fed mice
(Fig. 7B, C).
DISCUSSION
The major conclusions of our studies are that
blocking chylomicron assembly through conditional
deletion of intestinal Mttp mitigates the development of
hepatic steatosis in MCD-fed mice and reduces in-
flammatory and fibrogenic signaling. However, when
applied in either of two models of established steatosis
and fibrosis, blocking chylomicron assembly resulted in
efficient lipid mobilization and reduced hepatic stea-
tosis, yet failed to reverse inflammatory signaling and
fibrosis. Several features of the approach and conclu-
sions of this work merit further discussion in the
context of altered gut-liver signaling in the pathogen-
esis and therapeutic targeting of NAFLD.
Multiple lines of evidence point to a role for
impaired intestinal barrier function and bacterial
translocation in the pathogenesis of NAFLD and NASH
(31). Our prior findings in Mttp-IKO mice demonstrated
increased circulating levels of TNFα and exaggerated
colonic inflammation and injury during experimental
colitis (17). Those findings raised the suspicion that if
Mttp-IKO mice were fed an MCD diet, a model known to
promote intestinal barrier disruption and systemic
inflammation (32), there would be increased liver
injury. However, that was not the case. Despite the
further impairment of barrier function in Mttp-IKO
mice as evidenced by elevated serum FD-4 levels, Mttp-
IKO mice exhibited reduced inflammatory and fibro-
genic signaling. Those findings encouraged us to
consider whether conditional impairment of chylomi-
cron assembly might also reverse some of the key fea-
tures in models of established NAFLD/NASH. We were
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Fig. 5. Switching from HFFC to chow diet reverses steatosis but not inflammatory or fibrogenic signaling in male Mttp-IKO mice.
Abbreviations for all panels: HFFC, mice fed HFFC for 14 weeks; HFFC → chow, mice fed HFFC for 10 weeks and then chow for
4 weeks; HFFC → IKO chow, mice fed HFFC for 10 weeks and then chow for 4 weeks concomitant with induction of intestinal Mttp
deletion. A: Representative images of H&E-stained liver tissue (400×). B: Biochemical quantitation of hepatic lipid content, n = 5–10/
group. C: Representative images of Sirius red-stained liver tissue (200×), with quantitation of fibrotic area (right panel, n = 8–10/
group). D: Collagen content determined by hydroxyproline detection and normalized to protein content, n = 4–5/group.
E: Representative images of F4/80 staining (400×), with quantitation of F4/80-stained area shown at right (n = 4–5/group).
F: Relative abundance of the most abundant TG species presented as peak area ratio (n = 5/group). G: Indices of DNL, saturation
(SCD), and elongation calculated from peak area of all TG species (n = 5/group). H: Relative abundance of hepatic ceramide (Cer)
species, with total Cer peak area ratio shown on the far right (n = 5/group). I: mRNA expression of hepatic Cer synthase isoforms
(n = 5/group). For all panels, *P< 0.05 and **P < 0.01.
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further encouraged by other work showing that mice
with intestine-specific deletion of high mobility group
box 1 develop impaired intestinal lipid absorption with
decreased chylomicron formation, yet were protected
against diet-induced NASH (33).
However, despite the protection offered to Mttp-IKO
mice when fed an MCD diet, the induction of intestinal
Mttp deletion following the development of established
fibrosis not only failed to promote resolution but also
rather led to exaggerated injury and sustained inflam-
matory signaling. We modified our approach in the
reversal experiments with MCD feeding because of
continued weight loss and mortality associated with
prolonged exposure to this diet in Mttp-IKO mice, but
Fig. 6. Levels of oxidative stress and expression of NASH-related genes are unchanged in male Mttp-IKO mice following switch
from HFFC to chow diet. A: Liver TBARS content, n = 4–5/group, with levels in MCD-fed control mice shown for comparison.
B: Serum ALT, n = 9–10/group. C: Serum FITC-dextran FD4 levels 2 h after oral gavage, n = 5–7/group. D: mRNA expression of
genes related to fibrosis, inflammation, and lipogenesis (n = 6/genotype). E: Expression of total and phosphorylated JNK and NF-κB
proteins. A representative immunoblot and quantitation of relative protein expression levels are shown (n = 5/group). Abbreviations
are as outlined in the legend to Fig. 5. For all panels, *P < 0.05 and **P < 0.01.
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even 10 days of impaired chylomicron assembly in mice
fed an MCD diet resulted in worse fibrosis. Extending
the reversal time to 28 days, along with a switch to
regular chow, also failed to improve fibrosis in Mttp-IKO
mice. Because of concerns with MCD feeding as a
representative model of human NASH (34), we turned
to a second model in which high-fat feeding is sup-
plemented by fructose and cholesterol to augment
injury and inflammatory signaling (19, 20, 29, 30). This
model, herein referred to as HFFC and widely used in
various subtle iterations, produces less fibrotic injury
than MCD feeding but recapitulates other elements of
human NAFLD/NASH, including obesity, hepatic
steatosis, and metabolic dysfunction with insulin resis-
tance (34). We observed mild fibrosis in mice fed an
HFFC diet for 14 weeks but, as noted in MCD-fed mice,
we observed no fibrosis reversal in Mttp-IKO mice that
were switched to a chow diet for 4 weeks, despite
virtually complete elimination of hepatic steatosis.
It is worth noting that the decreased overall abun-
dance of hepatic lipid in MCD-fed Mttp-IKO mice was
accompanied by shifts in FA species distribution, with
relative preservation of 16:1 and 18:1 species accompa-
nied by upregulation of Scd1 mRNA expression and
indices of DNL. Those findings suggest that a compo-
nent of the adaptation to blocked chylomicron assem-
bly in Mttp-IKO mice involves increased hepatic
lipogenesis, which was observed in prior studies in
chow-fed Mttp-IKO mice (11, 12), along with increased
expression of hepatic Scd1 (12). Earlier work showed
that germ line Scd1 null mice were protected against
hepatic steatosis when fed an MCD diet, yet exhibited
more severe injury (35), whereas other work showed
that Scd1 null mice were protected against both hepatic
steatosis and inflammation in the setting of alcohol-
induced injury (36). Those findings, coupled with the
current observations in Mttp-IKO mice, suggest that the
adaptive induction of Scd1 expression and function
may mitigate the reversal of inflammatory signaling in
the setting of established steatosis and fibrotic injury
and further suggest that the overall distribution of FA
species rather than simply the quantity of hepatic lipid
is a key component of the injury phenotypes observed.
Those suggestions align with other work demonstrating
that switching WTmice from an HFFC diet to chow for
8 weeks reversed the hepatic steatosis but failed to
normalize hepatic FA distribution among neutral and
polar lipids (28). Among the key lipid signaling mole-
cules, we found increased hepatic Cer FA abundance in
Mttp-IKO mice in both dietary reversal models. Previous
studies demonstrated increased hepatic Cer content
following MCD feeding in mice (37, 38), and other work
has demonstrated that accumulation of specific Cer
species (C16:0 and C24:1) correlated with fibrogenic
activation in vitro in hepatic stellate cells (39). It is
possible that altered immune signaling in the livers of
mice plays a role in the continued inflammatory and
fibrogenic signaling following transition from either
MCD and/or HFFC feeding, based on increased
expression of damage-associated molecular patterns
and mediators, including Tlr4, Cd14, and Nlrp3
(supplemental Fig. S3), but further studies will be
required to consolidate those findings.
Fig. 7. Correlation between hepatic TG content and fibrotic
area. A: A positive association between hepatic TG content and
fibrotic area in maleMttp-IKOmice-fed MCD diet for 3 weeks. B:
No correlation between hepatic TG content and fibrotic area in
the MCD reversal experiments, including data from male and
female mice ± Mttp deletion with continued MCD feeding
(control, Mttp-IKO) and mice ± Mttp deletion concomitant with
switch to chow diet (→chow, →IKO chow). C: No correlation
between hepatic TG content and fibrotic area in the HFFC
reversal experiments. Groups include male mice-fed HFFC for
14 weeks, mice fed HFFC for 10 weeks, chow for 4 weeks (HFFC
→ chow), and mice fed HFFC for 10 weeks, chow for 4 weeks
with intestinal Mttp deletion (HFFC → IKO chow). Pearson
correlation coefficient (Pearson's r) and P values are shown on
each graph.
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Previous findings with regard to the metabolic
signaling pathways associated with impaired chylo-
micron assembly in Mttp-IKO mice suggest similarities
in the adaptive pathways to those observed in rodents
and humans undergoing bariatric surgery in-
terventions such as Roux-en-Y gastric bypass (14).
These include alterations in enterohepatic bile acid
signaling mediated via farnesoid X receptor and its
downstream targets fibroblast growth factor 15 as well
as through TGR5, which produce favorable metabolic
shifts in glucose and lipid metabolism and ameliora-
tion of hepatic steatosis (40, 41). However, while bar-
iatric surgical interventions have been reported to
successfully reverse the metabolic complications of
extreme obesity in patients, there are inconsistent
effects on the reversal of established hepatic fibrosis
(7, 42–44). Our studies were not designed to evaluate
the role of weight loss, but we note that both geno-
types fed the MCD diet exhibited weight loss during
active feeding and resumed weight gain upon
switching to a chow diet, with or without induction of
intestinal Mttp deletion (supplemental Fig. S2A). Mice
fed the HFFC diet for 10 weeks were obese, and there
was weight loss in mice switched to regular chow
along with induction of intestinal Mttp deletion
(supplemental Fig. S2B). Nevertheless, neither group
of mice exhibited reduction in fibrosis in the context
of those interventions. In addition, fasting glucose
levels were unchanged at terminal sacrifice in HFFC-
fed mice transitioned to chow but were reduced (as
expected) in HFFC-fed mice transitioned to Mttp-IKO
plus chow (supplemental Fig. S4). Those findings are
consistent with our prior demonstration that insulin
signaling is enhanced in Mttp-IKO mice and make it
unlikely that insulin resistance contributes to the
continued inflammatory and fibrogenic signaling
observed. Other recent findings demonstrated that
Mttp-IKO mice exhibit increased circulating levels of
incretins including GLP1, in association with delayed
gastric emptying and reduced hepatic gluconeogen-
esis (14). However, a recent phase II trial of the GLP1
agonist semaglutide demonstrated weight loss and
significant resolution of NASH (vs. placebo) but no
significant decrease in hepatic fibrosis (8). Taken
together with our current findings, these observations
raise implications in understanding the potential for
dietary and pharmacologic interventions in patients
with NAFLD. For example, we speculate that the
beneficial effects of sustained weight loss on reversal
of fibrosis may require a much longer period
following intervention, compared with the effects of
even modest weight loss on hepatic steatosis. A caveat
in this suggestion is that prolonged impairment of
chylomicron assembly with defective fat absorption
may be associated with essential fatty acid deficiency.
We did not specifically examine this possibility, but
future studies might incorporate determinations of
serum Mead acid (20:3; n-9) and other markers of
essential fatty acid deficiency as previously proposed
from our own and other laboratories (45, 46).
Earlier findings in mice treated with antisense oli-
gonucleotides to diacylglycerol acyltransferase
2 offer further insights in attempting to understand
the disconnect between resolution of hepatic steatosis
and inflammatory/fibrogenic signaling in experi-
mental NASH (47). Those workers treated groups of
mice following MCD feeding and observed that the
antisense-treated mice exhibited reduced steatosis, yet
worse inflammation and fibrosis than controls (47).
Our findings build upon those observations by
providing an independent approach to modifying
hepatic lipid content (i.e., blocking chylomicron as-
sembly) that occur despite adaptive changes in hepatic
lipogenesis.
We chose to examine the therapeutic potential for
conditionally blocking chylomicron assembly as an
intervention to mitigate progression and promote
reversal of NAFLD because of the continued unmet
need to understand the factors associated with liver-
related morbidity and mortality associated with
advanced forms of the disease including NASH (1). Our
focus on surrogate end points as intervention targets is
highlighted by recent studies from several population
cohorts demonstrating that hepatic fibrosis (as
confirmed by liver biopsy) is a major predictor of both
morbidity and mortality in patients with NAFLD and
NASH, even when corrected for confounding factors
(48). Our findings suggest that modifying chylomicron
assembly through approaches that impair intestinal
Mttp expression or function may represent a viable
therapeutic option for reversing established steatosis.
That being said, additional or alternative strategies will
be required to mitigate inflammatory and fibrogenic
signaling in patients with NASH.
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